Synonym
CGS 7525A; CGS-7525A; CGS7525A; Aptazapine maleate
IUPAC/Chemical Name
2-methyl-1,3,4,14b-tetrahydro-2H,10H-benzo[e]pyrazino[2,1-c]pyrrolo[1,2-a][1,4]diazepine maleate
InChi Key
JJTOHZLQMBVMPF-BTJKTKAUSA-N
InChi Code
InChI=1S/C16H19N3.C4H4O4/c1-17-9-10-19-14-6-3-2-5-13(14)11-18-8-4-7-15(18)16(19)12-17;5-3(6)1-2-4(7)8/h2-8,16H,9-12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
SMILES Code
CN(CC1)CC2N1C3=CC=CC=C3CN4C2=CC=C4.O=C(O)/C=C\C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related:
71576-41-5 (Aptazapine maleate)
71576-40-4 (Aptazapine free base).
Preparing Stock Solutions
The following data is based on the
product
molecular weight
369.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cirilli R, Orlando V, Ferretti R, Turchetto L, Silvestri R, De Martino G, La
Torre F. Direct HPLC enantioseparation of chiral aptazepine derivatives on coated
and immobilized polysaccharide-based chiral stationary phases. Chirality. 2006
Aug;18(8):621-32. PubMed PMID: 16715514.
2: Nishino S, Haak L, Shepherd H, Guilleminault C, Sakai T, Dement WC, Mignot E.
Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder
of rapid eye movement sleep. J Pharmacol Exp Ther. 1990 Jun;253(3):1145-52.
PubMed PMID: 1972749.
3: Gower AJ, Broekkamp CL, Rijk HW, Van Delft AM. Pharmacological evaluation of
in vivo tests for alpha 2-adrenoceptor blockade in the central nervous system and
the effects of the enantiomers of mianserin and its aza-analog ORG 3770. Arch Int
Pharmacodyn Ther. 1988 Jan-Feb;291:185-201. PubMed PMID: 2896489.
4: Gerhardt S, Liebman JM. Self-regulation of ICSS duration: effects of
anxiogenic substances, benzodiazepine antagonists and antidepressants. Pharmacol
Biochem Behav. 1985 Jan;22(1):71-6. PubMed PMID: 2858109.
5: DeHaas Vermeulen J, Thompson TA. Assay for the determination of the
tetracyclic antidepressant compound aptazapine in plasma by high-performance
liquid chromatography. J Chromatogr. 1984 Mar 9;306:412-6. PubMed PMID: 6715482.
6: Liebman JM, Lovell RA, Braunwalder A, Stone G, Bernard P, Barbaz B, Welch J,
Kim HS, Wasley JW, Robson RD. CGS 7525A, a new, centrally active alpha 2
adrenoceptor antagonist. Life Sci. 1983 Jan 24;32(4):355-63. PubMed PMID:
6131367.